MilliporeSigma, the US and Canada Life Science business of Merck KGaA, announced on Sept. 8, 2022, that it would be investing €130 million into its manufacturing plant in Molsheim, France. The expansion will increase capacity for the manufacturing of single-use assemblies belonging to MilliporeSigma’s Mobius portfolio. These additions include multiple 37,00 ft2 ISO7 clean rooms, an administrative building, and a new logistics warehouse, all of which are planned to be operational by the end of 2024 and at full production by 2028. Source: Biopharm International 14/9/2022